20/20 BIOLABS, INC. Contract Liability (Deferred Revenue)
20/20 BIOLABS, INC. (AIDX) had Contract Liability (Deferred Revenue) of $467.03 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Contract with Customer, Liability, Current $467.03K.
- 2026-03-31: Contract with Customer, Liability, Current $450.67K.
- 2025-12-31: Contract with Customer, Liability, Current $414.87K.
- 2024-12-31: Contract with Customer, Liability, Current $470.45K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $467.03K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $450.67K 10-Q · filed 2026-05-20 |
| 2025-12-31 | $414.87K 10-Q · filed 2026-08-14 |
| 2024-12-31 | $470.45K POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |